Other SGLT-2s in Development

The recent approval of Invokana is exciting, opening the door to a new class of medications that can help people to manage type 2 diabetes, but it was not exactly the only drug on that long road to approval. Take a look at other potential medications that are in various stages of trials and approvals that may join this newest class of oral medications.

Astellas Pharma – Ipragliflozin

  • This drug has been filed for marketing approval in Japan and is in the process of completing phase III trials.
  • Trials have shown its potential to significantly lower glycated hemoglobin levels (HbA1c) over time as compared to placebo.

Bi/Lilly – Empagliflozin

  • This drug is in Phase III of clinical trial process involving over 14,500 patients.  There will be a total of 12 clinical trials performed throughout several countries.
  • It is said that the companies will present results of the studies at some point in 2013 or 2014.

Chugai (Roche) – Tofogliflozin Hydrate

  • According to Chugai Pharma, as of November 2010, this drug is in Phase III of clinical trials.

Lexicon – LX4211

  • This drug inhibits both SGLT1 and SGLT2, making it the first of its kind to be introduced in clinical development for diabetes.
  • LX4211 will begin Phase III clinical studies in the middle of 2013.

Taisho Pharma – luseogliflozin

  • This drug is currently in Phase III of clinical trials.

Bristol-Myers Squibb Farxiga

  • This is a once- daily oral treatment specifically geared toward type 2 diabetes, to be used in conjunction with exercise and a proper diet. This treatment is currently in clinical trials.

Reviewed by James A. Bennett 04/14.

Last Modified Date: April 04, 2014

All content on dLife.com is created and reviewed in compliance with our editorial policy.
Sources
  1. • Astellas. AVEO and Astellas announce postive findings from TIVO-1 superiority study of tivozanib in first line advanced RCC., http://www.astellas.com/en/corporate/news/pdf/121003_Eg_1.pdf. (PDF) (Accessed 4/11/13.)
  2. • Lexicon Pharmaceuticals. LX4211, http://www.lexgen.com/pipeline/lx4211.html. (Accessed 4/11/13.)
  3. • Chugai Pharma USA. Annual report, 2011. http://www.chugai-pharm.co.jp/hc/ss/downloads/eAR2011_12_09.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3DeAR2011_12_09.pdf&blobwhere=1259656736395&ssbinary=true. (PDF) (Accessed 4/11/13.)
  4. • Theheart.org. FDA approves new diabetes drug, canagliflozin, despite CV concerns, http://www.theheart.org/article/1523789.do. (Accessed 4/11/13.)
  5. • Drug Discovery & Development Magazine. Lilly, BI submit empagliflozin to FDA, http://www.dddmag.com/news/2013/03/lilly-bi-submit-empagliflozin-fda. (Accessed 4/11/13.)

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
49 Views 0 comments
by Nicole Purcell
I was at boxing class the other day, and quite honestly I was taking my chances. I knew it. I had been low earlier in the day and used all of my emergency juice to treat that insulin reaction, leaving me at class (which is directly after work) with no juice whatsoever. No good. Of course, that day - the day I have no juice would be the exact day that diabetes picks to do its dirty work. Mid-class, I had a plummet. Just dropped to very low and but quick. I sat to test and...